Cassava Sciences stock price outlook is bearish despite insider buy

Cassava Sciences (NASDAQ: SAVA) stock price has been in a steep sell-off in the past few months as the enthusiasm of its pipeline wanes. Shares of the biopharmaceutical company were trading at $24.9 o...

Why the Dip in Cassava Sciences (SAVA) Stock Shouldn’t Spook You

Investors did not like the latest update from Alzheimer’s drug maker Cassava Sciences (NASDAQ:SAVA). After showing excellent results from the first 50 patients treated with simufilam, the compan...

Cassava Sciences Stock Shows Big Jump In Its Relative Strength Rating

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Cassava Sciences (SAVA) cleared that benchmark Wednesday, with a jump from 70 to 87 Wednesday. When looking for...

Should you buy Cassava Sciences as the stock continue to soar

Retail interest in Cassava Sciences (NASDAQ:SAVA) remains far from over. The stock gained more than 6.7% on Wednesday, catapulting it to a 76% increase in value in a month. The Wednesday gains came as...

Whales go bullish on SAVA stock: where to buy the Cassava Sciences stock

The Cassava Sciences stock (NASDAQ: SAVA) has been very bullish over the past month. It has gained more than 58% in a span of 30 days and investors are still bullish on the stock. Yesterday, a whale w...

Apple, Cassava Sciences, Canoo, more

Top trending after-hours tickers on Yahoo Finance: Apple (AAPL): Credit Suisse upgraded Apple to overweight from neutral, and raised the price target on the stock to $201 per share, implying a 16% ups...

This Analyst Goes Back to the Future to Recommend Cassava Stock

Six months ago Cassava Sciences (SAVA) had a problem. A citizen petition was logged with the FDA calling for a halt on the company’s simufilam drug for the treatment of Alzheimer’s Disease...

Here is where you can buy Cassava Sciences stock (SAVA): it is up 7% today

After dropping since mid-November, the price of Cassava Sciences stock (SAVA) has bounced back and today it is up 7.78%. The current bullish outlook is a result of a denial by the FDA against Citizen ...

Cassava: An Attractive Value Proposition

Let’s rewind back to the start of last year, to a period when Cassava Sciences (SAVA) shares began their ascent to a higher place; investors had evidently cottoned on to the potential of the company’s...